Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2017–2021

GLIOTRAIN · Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2017-09-01 → 2021-08-31
EU contribution
€3,836,772
Participants
23
Scheme
MSCA-ITN-ETN

Lines connect the coordinator with its partners.

Results in brief

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Worldwide there are c. 240,000 cases of brain and nervous system tumours per year. Glioblastoma (GBM) is the most frequent and aggressive. Despite significant efforts clinicians remain unable to offer curative therapy. 85% of patients die within 2 years despite aggressive treatment (surgical resection + radio-chemotherapy + temozolomide). Diverse elements underpin the intractability of GBM including its infiltrative nature, rapid proliferative rate, treatment resistance, the blood brain barrier impeding access of drugs, activation of multiple signal transduction pathways/specific gene mutations and intra/inter-tumoural heterogeneity. New treatment options and effective precision medicine therapies are urgently required. The objective of GLIOTRAIN was to exploit the intractability of GBM to address European applied biomedical research training needs, to identify novel therapeutic strategies for application in GBM and unravel disease resistance mechanisms.

Data: CORDIS, © European Union

Project objective

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Original text from CORDIS.

Participants

  • ROYAL COLLEGE OF SURGEONS IN IRELAND · DUBLIN 2CoordinatorIreland
  • AGILENT TECHNOLOGIES BELGIUM NV · DIEGEMBelgium
  • BMS France · ArgonayFrance
  • CANCER TRIALS IRELAND COMPANY LIMITED BY GUARANTEE · DUBLIN 2Ireland
  • CARTHERA · PARISFrance
  • Champions Oncology, Inc. · Hackensack, NJUnited States
  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM · RotterdamNetherlands
  • GENEXPLAIN GMBH · WolfenbuttelGermany
  • INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA · Esch-UelzechtLuxembourg
  • INSILICO BIOTECHNOLOGY AG · StuttgartGermany
  • INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE · ParisFrance
  • INTERNATIONAL BRAIN TUMOUR ALLIANCE · LONDONUnited Kingdom
  • KATHOLIEKE UNIVERSITEIT LEUVEN · LeuvenBelgium
  • LUXEMBOURG INSTITUTE OF HEALTH · StrassenLuxembourg
  • MEDIZINISCHE HOCHSCHULE HANNOVER · HannoverGermany
  • MIMETAS BV · LeidenNetherlands
  • Oncurious NV · LeuvenBelgium
  • Pepscope BV · UtrechtNetherlands
  • TEVA PHARMACEUTICALS EUROPE B.V. · AMSTERDAMNetherlands
  • UNIVERSITE DU LUXEMBOURG · ESCH-SUR-ALZETTELuxembourg
  • UNIVERSITY OF STUTTGART · StuttgartGermany
  • VIB VZW · ZWIJNAARDE - GENTBelgium
  • YUMAB GmbH · BraunschweigGermany

Links

Data: CORDIS, © European Union